Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma-论文-万方医学网

首页> > Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma

Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma

导出原文传递

翻译打印收藏纠错

第一作者： Ohno, Makoto

作者： Ohno, Makoto ^[1] ; Miyakita, Yasuji ; Takahashi, Masamichi ; Yanagisawa, Shunsuke ; Tamura, Yukie ; Narita, Yoshitaka

作者单位： National Cancer Center - Japan,Natl Canc Ctr ^[1]

关键词 glioblastoma IDH 1 2-wildtype temozolomide maintenance therapy Karnofsky performance status long-term survival NEWLY-DIAGNOSED GLIOBLASTOMA ADJUVANT TEMOZOLOMIDE PROLONGED TEMOZOLOMIDE IDH1/2 MUTATIONS ELDERLY-PATIENTS SURVIVAL RADIOTHERAPY BEVACIZUMAB TRIAL

发布时间 2022-11-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma

相似文献

同项目论文

相关期刊

检索历史 清除

Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma

相似文献

同项目论文

相关期刊

检索历史清除